Skip to content

Manuscripts

Scientific manuscripts are developed in collaboration with key experts and are published in peer-reviewed journals.

This page is intended as an educational resource for U.S. healthcare professionals. The list of Acadia-sponsored manuscripts below may contain information about doses, uses, formulations, and populations different from product labeling or contain information about investigational compounds or uses not approved by the FDA. Please refer to the product’s Full Prescribing Information.

Search
Area of Focus
Filters applied:
  • December 17, 2024
  • Manuscript
Healthcare resource utilization patterns among patients with Parkinson’s disease psychosis: Analysis of individuals covered by Medicare and treated with pimavanserin or other atypical antipsychotics

Future Neurology

  • November 18, 2024
  • Manuscript
Trofinetide benefits the ability to communicate in Rett syndrome: a plain language summary of the LAVENDER trial

Future Rare Diseases

  • August 7, 2024
  • Manuscript
Characterizing the journey of Rett syndrome among females in the United States: a real-world evidence study using the Rett syndrome natural history study database

Journal of Neurodevelopmental Disorders

  • July 17, 2024
  • Manuscript
Trofinetide for the treatment of Rett syndrome: Long-term safety and efficacy results of the 32-month, open-label LILAC-2 study

Med

  • July 15, 2024
  • Manuscript
Improvement in symptoms of Rett syndrome with trofinetide beyond clinical trial efficacy assessments: case reports

Future Rare Diseases

  • July 4, 2024
  • Manuscript
Effect of Hepatic Impairment on Trofinetide Exposures Using an In Silico Physiologically Based Pharmacokinetic Model

Advances in Therapy

  • June 24, 2024
  • Manuscript
Trofinetide for the treatment of Rett syndrome: Results from the open-label extension LILAC study

Med

  • June 13, 2024
  • Manuscript
Recommendations for the management of gastrointestinal comorbidities with or without trofinetide use in Rett syndrome

Expert Review of Gastroenterology & Hepatology

  • March 11, 2024
  • Manuscript
Analysis of Medicare patients treated with pimavanserin versus other atypical antipsychotics: a cost-offset model evaluating skilled nursing facility stays and long-term care admissions in Parkinson’s disease psychosis

ClinicoEconomics and Outcomes Research

  • March 11, 2024
  • Manuscript
The effects of treatment with pimavanserin on activities of daily living in subjects with Parkinson’s disease psychosis (PDP): a 16-week open-label study

Therapeutic Advances in Neurological Disorders

  • March 7, 2024
  • Manuscript
Safety profile of pimavanserin therapy in elderly patients with neurodegenerative disease-related neuropsychiatric symptoms: a phase 3B study

Journal of Alzheimer's Disease

  • March 1, 2024
  • Manuscript
Trofinetide treatment demonstrates a benefit over placebo for the ability to communicate in Rett syndrome

Pediatric Neurology

  • February 20, 2024
  • Manuscript
Managing gastrointestinal symptoms resulting from treatment with trofinetide for Rett syndrome: caregiver and nurse perspectives

Advances in Therapy

  • February 16, 2024
  • Manuscript
Exposure-response efficacy modeling to support trofinetide dosing in individuals with Rett syndrome

Advances in Therapy

  • February 1, 2024
  • Manuscript
A physiologically based pharmacokinetic modeling approach to assess the potential for drug interactions between trofinetide and CYP3A4 metabolized drugs

Clinical Therapeutics

  • February 1, 2024
  • Manuscript
Pimavanserin for psychosis in Parkinson’s disease dementia: subgroup analysis of the HARMONY trial

Parkinsonism & Related Disorders

  • January 22, 2024
  • Manuscript
Development of trofinetide for the treatment of Rett syndrome from bench to bedside

Frontiers in Pharmacology

  • January 19, 2024
  • Manuscript
Adherence to background antipsychotic and pimavanserin in patients with schizophrenia: post hoc analyses from the ENHANCE and ADVANCE trials

Patient Preferenece and Adherence

  • December 15, 2023
  • Manuscript
Risk of long-term care admissions among Medicare beneficiaries treated with pimavanserin or quetiapine for Parkinson’s disease psychosis in the US: a retrospective administrative claims data base analysis

Journal of Comparative Effectiveness Research

  • December 1, 2023
  • Manuscript
Population pharmacokinetic modeling and stochastic simulations to support pediatric dose selection of pimavanserin

The Journal of Clinical Pharmacology

  • November 28, 2023
  • Manuscript
Characterization of the pharmacokinetics and mass balance of a single oral dose of trofinetide in healthy male subjects

Clinical Drug Investigation

  • November 16, 2023
  • Manuscript
Gastrointestinal manifestations in pediatric and adult patients with Rett syndrome: an analysis of US claims and physician survey data

Journal of Comparative Effectiveness Research

  • November 7, 2023
  • Manuscript
Incremental health care resource utilization and costs associated among patients with Parkinson’s disease psychosis and incident dementia: an analysis of Medicare beneficiaries

International Journal of Geriatric Psychiatry

  • August 8, 2023
  • Manuscript
A plain language summary of results from the LAVENDER study: trofinetide treatment for Rett syndrome

Future Rare Diseases

  • July 28, 2023
  • Manuscript
A review of the Rett Syndrome Behaviour Questionnaire and its utilization in the assessment of symptoms associated with Rett syndrome

Frontiers in Pediatrics

  • June 13, 2023
  • Manuscript
Patients treated with pimavanserin or quetiapine for Parkinson’s disease psychosis: analysis of health resource utilization patterns among Medicare beneficiaries

Journal of Medical Economics

  • June 8, 2023
  • Manuscript
Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study

Nature Medicine

  • May 9, 2023
  • Manuscript
Meaningful improvements in Rett syndrome: a qualitative study of caregivers

Journal of Child Neurology

  • May 1, 2023
  • Manuscript
Exposure-response modeling from the CLARITY trial of pimavanserin for adjunctive treatment of major depressive disorder

Clinical Pharmacology in Drug Development

  • March 4, 2023
  • Manuscript
Epidemiology and patient journey of Rett Syndrome in the United States: a real-world evidence study

BMC Neurology

  • February 1, 2023
  • Manuscript
Mortality in patients with Parkinson’s disease-related psychosis treated with pimavanserin compared with other atypical antipsychotics: a cohort study

Drug Safety

  • January 15, 2023
  • Manuscript
Pimavanserin reverses multiple measures of anxiety in a rodent model of post-traumatic stress disorder

European Journal of Pharmacology

  • January 9, 2023
  • Manuscript
Characteristics, conditions, and healthcare service utilization patterns of individuals diagnosed with Rett syndrome: an analysis of administrative claims data

Future Rare Diseases

  • January 9, 2023
  • Manuscript
Recommendations for managing diarrhea from trofinetide use with Rett syndrome: a plain language summary

Future Rare Diseases

  • January 1, 2023
  • Manuscript
Burden of illness among patients with psychosis due to dementia with Lewy bodies and other dementias

American Journal of Alzheimer's Disease & Other Dementias

  • January 1, 2023
  • Manuscript
Health care resource utilization patterns among patients with Parkinson’s disease psychosis: analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics

Journal of Medical Economics

  • December 14, 2022
  • Manuscript
Mortality risk in patients with Parkinson’s disease-related psychosis treated with pimavanserin compared with other atypical antipsychotics: a cohort study

Drug Safety

  • November 20, 2022
  • Manuscript
Pimavanserin exposure–response analyses in patients with schizophrenia. Results from the phase 2 ADVANCE study

Journal of Clinical Psychiatry

  • October 27, 2022
  • Manuscript
Adjunctive pimavanserin in patients with major depressive disorder: combined results from two randomized, double-blind, placebo-controlled, phase 3 studies

Psychopharmacology Bulletin

  • October 6, 2022
  • Manuscript
Clinical outcomes and treatment patterns of older adults with dementia-related psychosis by dementia type in the United States

BMC Geriatrics

  • October 5, 2022
  • Manuscript
Motor- and cognition-related safety of pimavanserin in patients with Parkinson’s disease psychosis

Frontiers in Neurology

  • October 1, 2022
  • Manuscript
Role of pimavanserin treatment-continuity on discharge from long-term care: assessing the quality of antipsychotic medication review

Senior Care Pharmacist

  • September 6, 2022
  • Manuscript
Effects of adjunctive pimavanserin and current antipsychotic treatment on QT interval prolongation in patients with schizophrenia

Frontiers in Psychiatry

  • August 1, 2022
  • Manuscript
Hallucinations and delusions associated with Parkinson’s disease psychosis: safety of current treatments and future directions

Expert Opinion on Drug Safety

  • July 29, 2022
  • Manuscript
Screening, diagnosis, and management of Parkinson’s disease psychosis: recommendations from an expert panel

Neurology and Therapy

  • July 23, 2022
  • Manuscript
Using telemedicine to assess and manage psychosis in neurodegenerative diseases in long-term care

Journal of the American Medical Directors Association

  • June 24, 2022
  • Manuscript
Relapse in dementia-related psychosis and clinical decisions

Alzheimer Disease & Associated Disorders

  • May 18, 2022
  • Manuscript
Incidence, prevalence, and mortality of psychosis associated with Parkinson disease (1991-2010)

Journal of Parkinson’s Disease

  • May 14, 2022
  • Manuscript
Unmet needs in the diagnosis and treatment of dementia-related psychosis and Parkinson’s disease psychosis

International Journal of Psychiatry in Clinical Practice

  • May 9, 2022
  • Manuscript
Symptoms and treatment needs of people with dementia-related psychosis: a mixed-methods study of the patient experience

Clinical Gerontologist

  • March 26, 2022
  • Manuscript
Pimavanserin augments the efficacy of atypical antipsychotic drugs in a mouse model of treatment-refractory negative symptoms of schizophrenia

Behavioural Brain Research

  • March 23, 2022
  • Manuscript
Impact of isolation during the COVID-19 pandemic on the patient burden of Parkinson’s disease: a PMD Alliance survey

Neuropsychiatric Disease and Treatment

  • March 22, 2022
  • Manuscript
In vitro stability and recovery studies of pimavanserin in water and in different vehicles orally administered

Drugs in R&D

  • March 9, 2022
  • Manuscript
Falls and fractures in patients with Parkinson’s disease-related psychosis treated with pimavanserin vs atypical antipsychotics: a cohort study

Drugs - Real World Outcomes

  • March 8, 2022
  • Manuscript
Economic evaluation of healthcare resource utilization and costs for newly diagnosed dementia-related psychosis

Geriatrics (Basel)

  • March 8, 2022
  • Manuscript
Healthcare resource utilization and costs for newly diagnosed dementia-related psychosis

Geriatrics

  • March 7, 2022
  • Manuscript
Barriers to treatment of hallucinations and delusions in people with dementia residing in long-term care

Journal of Clinical Psychiatry

  • March 5, 2022
  • Manuscript
Comparative outcomes of commonly used off-label atypical antipsychotics in the treatment for dementia-related psychosis: a network meta-analysis

Advances in Therapy

  • February 27, 2022
  • Manuscript
Dementia-related psychosis and the potential role for pimavanserin

Dementia-related psychosis and the potential role for pimavanserin

  • February 8, 2022
  • Manuscript
Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome

Contemporary Clinical Trials

  • January 28, 2022
  • Manuscript
The impact of pimavanserin on psychotic phenotypes and tau phosphorylation in the P301L/COMT– and rTg(P301L)4510 mouse models of Alzheimer’s disease

Alzheimer’s & Dementia

  • January 27, 2022
  • Manuscript
Treatment patterns with antipsychotics in long-term care patients with Parkinson’s disease psychosis

Journal of Applied Gerontology

  • January 24, 2022
  • Manuscript
Adverse outcomes associated with off-label agents used to treat dementia patients with psychosis: a case-control Medicare database study

American Journal of Alzheimer’s Disease and Other Dementias

  • January 9, 2022
  • Manuscript
Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe

Lancet Psychiatry

  • January 8, 2022
  • Manuscript
ENHANCE: phase 3, randomized, double-blind, placebo-controlled study of adjunctive pimavanserin for schizophrenia in patients with an inadequate response to antipsychotic treatment

Schizophrenia Bulletin Open

  • August 4, 2021
  • Manuscript
Comparative efficacy, safety, tolerability, and effectiveness of antipsychotics in the treatment of dementia-related psychosis (DRP): a systematic literature review

The Journal of Prevention of Alzheimer's Disease

  • July 22, 2021
  • Manuscript
Trial of pimavanserin in dementia-related psychosis

The New England Journal of Medicine

  • July 5, 2021
  • Manuscript
Relevance of 5-HT2A receptor modulation of pyramidal cell excitability for dementia-related psychosis: implications for pharmacotherapy

CNS Drugs

  • June 15, 2021
  • Manuscript
Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson’s disease psychosis patients

Parkinsonism & Related Disorders

  • June 1, 2021
  • Manuscript
Pimavanserin promotes trophic factor release and protects cultured primary dopaminergic neurons exposed to MPP+ in a GDNF-dependent manner

ACS Chemical Neuroscience

  • May 31, 2021
  • Manuscript
Real-world medication treatment patterns for long-term care residents with dementia-related psychosis

Gerontology and Geriatric Medicine

  • March 27, 2021
  • Manuscript
Burden of illness among patients with dementia-related psychosis

Journal of Managed Care & Specialty Pharmacy

  • March 23, 2021
  • Manuscript
Association of dementia-related psychosis with long-term care use and death

Neurology

  • January 27, 2021
  • Manuscript
Increased risk of falls and fractures in patients with psychosis and Parkinson disease

PLoS One

  • January 10, 2021
  • Manuscript
Pimavanserin, a 5HT 2A receptor inverse agonist, rapidly suppresses Aβ production and related pathology in a mouse model of Alzheimer’s disease

Journal of Neurochemistry

  • January 4, 2021
  • Manuscript
Pimavanserin treatment for Parkinson’s disease psychosis in clinical practice

Parkinson’s Disease

  • December 1, 2020
  • Manuscript
Effect of adjunctive pimavanserin on suicidal ideation in patients with major depression: analysis of the CLARITY study

Journal of Affective Disorders

  • November 25, 2020
  • Manuscript
Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer’s disease psychosis: a post hoc analysis

International Journal of Geriatric Psychiatry

  • November 15, 2020
  • Manuscript
Blinded SAPS-PD assessment after 10 weeks of pimavanserin treatment for Parkinson’s disease psychosis

Journal of Parkinson’s Disease

  • November 4, 2020
  • Manuscript
An open-label, 8-week study of safety and efficacy of pimavanserin treatment in adults with Parkinson’s disease and depression

Journal of Parkinson’s Disease

  • November 1, 2020
  • Manuscript
Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the CLARITY study

International Clinical Psychopharmacology

  • June 28, 2020
  • Manuscript
Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson’s disease psychosis

Parkinsonism & Related Disorders

  • May 1, 2020
  • Manuscript
Improvement of sexual function during treatment of major depressive disorder with adjunctive pimavanserin: a secondary analysis

Depression and Anxiety

  • November 20, 2019
  • Manuscript
Inverse agonists of the 5-HT2A receptor reduce nicotine withdrawal signs in rats

Neuroscience Letters

  • October 24, 2019
  • Manuscript
Increases in institutionalization, healthcare resource utilization, and mortality risk associated with Parkinson disease psychosis: retrospective cohort study

Parkinsonism & Related Disorders

  • September 24, 2019
  • Manuscript
A phase 2, randomized, double-blind, placebo-controlled study of adjunctive pimavanserin in patients with major depressive disorder and an inadequate response to therapy (CLARITY)

The Journal of Clinical Psychiatry

  • August 5, 2019
  • Manuscript
Impact of non-motor symptoms in Parkinson’s disease: a PMDAlliance survey

Neuropsychiatric Disease and Treatment

  • July 1, 2019
  • Manuscript
Changing the treatment paradigm for Parkinson’s disease psychosis with pimavanserin

Expert Review of Clinical Pharmacology

  • April 16, 2019
  • Manuscript
Double-blind, randomized, placebo‐controlled study of trofinetide in pediatric Rett syndrome

Neurology

  • January 1, 2019
  • Manuscript
Pimavanserin in Alzheimer’s disease psychosis: efficacy in patients with more pronounced psychotic symptoms.

The Journal of Prevention of Alzheimer's Disease

  • December 1, 2018
  • Manuscript
Nighttime sleep and daytime sleepiness improved with pimavanserin during treatment of Parkinson’s disease psychosis

Clinical Neuropharmacology

  • November 1, 2018
  • Manuscript
Pimavanserin for Parkinson’s disease psychosis: effects stratified by baseline cognition and use of cognitive-enhancing medications

Movement Disorders

  • October 1, 2018
  • Manuscript
Pimavanserin: potential treatment for dementia-related psychosis

The Journal of Prevention of Alzheimer's Disease

  • June 1, 2018
  • Manuscript
Pimavanserin for the treatment of Parkinson’s disease psychosis: number needed to treat, number needed to harm, and likelihood to be helped or harmed

CNS Spectrums

  • March 1, 2018
  • Manuscript
Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer’s disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study

Lancet Neurology

  • November 1, 2017
  • Manuscript
A double-blind, randomized, placebo-controlled clinical study of trofinetide in the treatment of Rett syndrome

Pediatric Neurology

  • June 1, 2017
  • Manuscript
The emerging role of pimavanserin in the management of Parkinson’s disease psychosis

Journal of Managed Care & Specialty Pharmacy

  • August 1, 2015
  • Manuscript
Parkinson’s disease psychosis: symptoms, management, and economic burden

The American Journal of Managed Care

  • October 1, 2014
  • Manuscript
On the discovery and development of pimavanserin: a novel drug candidate for Parkinson’s psychosis

Neurochemical Research

  • February 8, 2014
  • Manuscript
Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial

Lancet

  • October 1, 2013
  • Manuscript
Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson’s disease and Parkinson’s disease psychosis: evaluation of therapeutic ratios

Behavioural Pharmacology

  • March 1, 2013
  • Manuscript
Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson’s disease psychosis

Parkinsonism & Related Disorders

  • November 1, 2012
  • Manuscript
Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2 mg/day, but does not enhance efficacy of haloperidol, 2 mg/day: comparison with reference dose risperidone, 6 mg/day

Schizophrenia Research

  • August 1, 2012
  • Manuscript
Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer’s disease

Behavioural Pharmacology

  • October 1, 2011
  • Manuscript
Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson’s disease

Behavioural Pharmacology

  • March 1, 2010
  • Manuscript
Pimavanserin, a serotonin2A receptor inverse agonist, for the treatment of Parkinson’s disease psychosis

Neuropsychopharmacology

  • October 1, 2008
  • Manuscript
A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model

Pharmacology Biochemistry and Behavior

  • March 1, 2008
  • Manuscript
PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain

The International Journal of Neuropsychopharmacology

  • August 1, 2007
  • Manuscript
ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models

The Journal of Pharmacology and Experimental Therapeutics

  • May 1, 2006
  • Manuscript
Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N’-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine2A receptor inverse agonist

The Journal of Pharmacology and Experimental Therapeutics

  • July 1, 2003
  • Manuscript
Psychosis of Parkinson’s disease: serotonin 2A inverse agonists as potential therapeutics

Current Opinion in Investigational Drugs

111 Results

To report an Adverse Event or Product Complaint please call (844) 422-2342.

Important Note

This page is intended as an educational resource for U.S. healthcare professionals. The list of Acadia-sponsored publications below may contain information about doses, uses, formulations and populations different from product labelling or contain information about investigational compounds or uses not approved by the FDA.

I certify that I am a licensed health care provider in the U.S.

Important Note

You are now being redirected

You are now leaving acadia.com

You are about to leave acadia.com. You will be redirected to a third party website not affiliated with Acadia Pharmaceuticals Inc.
Do you want to continue?

You are leaving our {{LEAVING_REGION}} website and going to our {{ENTERING_REGION}} website, which is in {{ENTERING_LANGUAGE}}.
The information you are about to be referred to may not comply with the local regulatory requirements.
Do you want to continue?

You are now being directed to another Acadia website that contains information about specific treatment(s).
Do you want to continue?

Continue